![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: STATH |
Gene summary for STATH |
![]() |
Gene information | Species | Human | Gene symbol | STATH | Gene ID | 6779 |
Gene name | statherin | |
Gene Alias | STR | |
Cytomap | 4q13.3 | |
Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | P02808 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6779 | STATH | C46 | Human | Oral cavity | OSCC | 1.13e-04 | 4.39e+00 | 0.1673 |
6779 | STATH | LN46 | Human | Oral cavity | OSCC | 9.05e-12 | 4.31e-01 | 0.1666 |
6779 | STATH | SYSMH6 | Human | Oral cavity | OSCC | 3.07e-117 | 8.10e+00 | 0.1275 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | ![]() |
Stomach | SIM | ![]() |
Liver | NAFLD | ![]() |
Liver | Cirrhotic | ![]() |
Liver | HCC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000150310 | Oral cavity | OSCC | ossification | 203/7305 | 408/18723 | 5.54e-06 | 6.19e-05 | 203 |
GO:005087819 | Oral cavity | OSCC | regulation of body fluid levels | 179/7305 | 379/18723 | 6.19e-04 | 3.50e-03 | 179 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STATH | SNV | Missense_Mutation | c.65N>G | p.Ser22Cys | p.S22C | P02808 | protein_coding | deleterious_low_confidence(0.04) | probably_damaging(0.983) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
STATH | SNV | Missense_Mutation | novel | c.174A>C | p.Gln58His | p.Q58H | P02808 | protein_coding | deleterious_low_confidence(0) | benign(0.005) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STATH | SNV | Missense_Mutation | novel | c.106G>T | p.Gly36Trp | p.G36W | P02808 | protein_coding | tolerated_low_confidence(0.2) | possibly_damaging(0.868) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
STATH | SNV | Missense_Mutation | c.6N>T | p.Lys2Asn | p.K2N | P02808 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.946) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
STATH | SNV | Missense_Mutation | novel | c.68N>G | p.Glu23Gly | p.E23G | P02808 | protein_coding | deleterious_low_confidence(0) | benign(0.077) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STATH | SNV | Missense_Mutation | c.31G>T | p.Ala11Ser | p.A11S | P02808 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.998) | TCGA-BS-A0V8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
STATH | SNV | Missense_Mutation | c.30G>T | p.Leu10Phe | p.L10F | P02808 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.798) | TCGA-49-AAR2-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | taxol | CR | |
STATH | SNV | Missense_Mutation | c.185T>A | p.Phe62Tyr | p.F62Y | P02808 | protein_coding | deleterious_low_confidence(0) | benign(0.029) | TCGA-66-2793-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
STATH | deletion | Frame_Shift_Del | c.116delC | p.Pro39LeufsTer33 | p.P39Lfs*33 | P02808 | protein_coding | TCGA-69-7979-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |